Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Altimmune (ALT) over the last 17 years, with Q3 2025 value amounting to -$149.3 million.

  • Altimmune's Cash from Investing Activities fell 1255379.48% to -$149.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$39.7 million, marking a year-over-year increase of 2059.75%. This contributed to the annual value of -$28.4 million for FY2024, which is 30671.42% down from last year.
  • As of Q3 2025, Altimmune's Cash from Investing Activities stood at -$149.3 million, which was down 1255379.48% from $101.1 million recorded in Q2 2025.
  • Altimmune's Cash from Investing Activities' 5-year high stood at $101.1 million during Q2 2025, with a 5-year trough of -$149.3 million in Q3 2025.
  • Moreover, its 5-year median value for Cash from Investing Activities was $1.2 million (2024), whereas its average is -$2.8 million.
  • In the last 5 years, Altimmune's Cash from Investing Activities surged by 14790000.0% in 2023 and then plummeted by 1255379.48% in 2025.
  • Quarter analysis of 5 years shows Altimmune's Cash from Investing Activities stood at $24.9 million in 2021, then tumbled by 96.06% to $981000.0 in 2022, then tumbled by 911.31% to -$8.0 million in 2023, then soared by 271.28% to $13.6 million in 2024, then plummeted by 1195.37% to -$149.3 million in 2025.
  • Its Cash from Investing Activities stands at -$149.3 million for Q3 2025, versus $101.1 million for Q2 2025 and -$5.1 million for Q1 2025.